Topics and Expertise: pharmacokinetics

A large trial of a new drug regimen for tuberculosis, designed in part by School researchers, leads to a new WHO recommendation for treating the disease.

Low-cost drug treatments can cure TB and malaria. Why, then, do these diseases claim so many lives?

Pharmacokinetics for Pharmaceutical Scientists is an annual course, now in its 30th year.

In people with type 2 diabetes, the body is less able to use the hormone insulin to regulate blood sugar. The disease affects 350 million patients globally—including 29 million in the United States, where it is the leading cause of blindness, kidney failure, and non-accident-related amputations.

Allopurinol, the first-choice medication for treating gout—an excruciatingly painful condition that is the most common form of inflammatory arthritis, afflicts more than eight million Americans, and is on the rise worldwide—is not fully effective in more than half of patients.

Table of contents

Introduction
Budget significance
Reasons for past success
A decade of funding for bioinformatics
New drug discovery directions attract support
Research stalwarts draw funding for decades
New directions in translational research attract support
Expansion of the School’s...

Kathy M. Giacomini, PhD, chair, department of biopharmaceutical sciences and Leslie Z. Benet, PhD, professor in the same department, were both honored at the Pharmaceutical Sciences World Congress, held May 29 to June 4, 2004 in Kyoto, Japan.